Clinical Trial Update: Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of cabozantinib as monotherapy in advanced cholangiocarcinoma completed; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Cholangiocarcinoma Extrahepatic
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Cabozantinib (XL-184) (cabozantinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Bile Duct Cancer, Intrahepatic Cholangiocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-03